Meeting slides
Interactive presentation
Scientific Insights Into Incretin Signaling and Type 2 Diabetes
Vivian Fonseca, MD, FRCP
Suggested Readings
Standards of medical care in diabetes—2014.
American Diabetes Association. Diabetes Care. 2014;37(suppl 1):S14-S18.
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.
AACE comprehensive diabetes management algorithm 2013.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract. 2013;19:327-336.
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Diabetes Care. 2011;34 (suppl 2):S251-S257.
Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.
Horton ES, Silberman C, Davis KL, Berria R. Diabetes Care. 2010;33:1759-1765.
GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D. Cardiovasc Ther. 2013;31:238-249.
Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.
Macconell L, Pencek R, Li Y, Maggs D, Porter L. Diabetes Metab Syndr Obes. 2013;6:31-41.
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
Stolar MW, Grimm M, Chen S. Diabetes Metab Syndr Obes. 2013;6:435-444.
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.
Tschope D, Hanefeld M, Meier JJ, et al. Cardiovasc Diabetol. 2013;12:62.
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B, Zhong J, Lin H, et al. Diabetes Obes Metab. 2013;15:737-749.